St. Jude Outlines Strategy To Revive Pacemaker Business
This article was originally published in The Gray Sheet
St. Jude Medical’s pacemaker revenue dropped 12 percent year-over-year in the first quarter, but the firm says it has several products in the pipeline that could help it regain pacemaker market share in Europe and Japan.
You may also be interested in...
St. Jude paid $123.5 million and agreed to up to $65 million in additional milestone payments to acquire Nanostim and its first-in-class leadless pacemaker, which has just earned a CE mark and is expected to launch in select European markets soon.
The first commercial implant for St. Jude’s Allure Quadra in Hong Kong is a sign for optimism for its pacemaker business after last year’s disappointments in Japan.
The firm reported during its second-quarter earnings call that its cardiac rhythm management business has stabilized after several quarters of market share decline.